148 results about "Bcl-2 Genes" patented technology

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

Inhibitors of Bcl-2 / Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2 / Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2 / Bcl-xL provides a benefit, like cancers, also are disclosed.

Inhibitors of Bcl-2 / Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2 / Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2 / Bcl-xL provides a benefit, like cancers, also are disclosed.

Bcl-xL / Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL / Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL / Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells.